Intravenous XXXX prophylaxis for @entity955 after coronary artery bypass surgery.

@entity1 @entity2399 @entity74 @entity955 @entity943
OBJECTIVE: @entity955 is a @entity74 commonly seen early after coronary artery bypass grafting, and it increases morbidity. METHODS: To investigate the effectiveness of @entity2399 in the prophylaxis of @entity955 , we conducted a prospective, randomized, placebo-controlled clinical study on 200 consecutive @entity1 in whom we performed elective and initial coronary artery bypass grafting operations. In each group 50% of @entity1 underwent beating-heart operations. In the treatment group 100 @entity1 (76 @entity1 and 24 @entity1 ; mean age, 57.63 +/- 9.68 years) received 24.34 mEq (3 g) of @entity2399 in 100 mL of saline solution that was administered over 2 hours (50 mL/h) preoperatively, perioperatively, and at postoperative days 0, 1, 2, and 3. In the control group 100 @entity1 (74 @entity1 and 26 @entity1 ; mean age, 59.96 +/- 9.29 years) received only 100 mL of saline solution according to the same administration schedule as the treatment group. RESULTS: @entity955 developed in 15 @entity1 from the treatment group and in 16 @entity1 from the control group. The @entity943 developed after 37.87 +/- 12.76 and 45.26 +/- 15.27 hours in the treatment and control groups, respectively. Although a significant relationship was found between low @entity2399 levels and increased incidence of @entity955 (P <.05), when the incidence of postoperative @entity955 is concerned, no significant difference was found between the 2 groups (P >.05). Also, no significant difference was found between operations with cardiopulmonary bypass and beating-heart operations in terms of @entity955 incidence (P >.05). However, @entity955 extended the duration of hospital stay in both groups (P <.05). CONCLUSION: Our findings indicate that @entity2399 infusion alone is not sufficient for the prophylaxis of @entity955 .
